Paul Negulescu
Senior Vice President & Disease Area Executive Vertex Pharmaceuticals
Paul is a Senior Vice President of Research at Vertex Pharmaceuticals, where he is currently Disease Area Executive for Vertex’s Pain Program. From 2003-2022 Paul was Site Head for Vertex’s San Diego Research Site which focused on developing treatments for Cystic fibrosis and pain. Paul and his team pioneered the development of CFTR modulators which restore the function of the defective CFTR protein, resulting in five marketed products (Kalydeco, Orkambi, Symdeko, Trikafta, Alyftrek). Trikafta and Alyftrek are triple drug combinations that could treat approximately 90% of people with CF. In pain, Paul and his team discovered and developed the first marketed selective NaV1.8 channel inhibitor (Journavx) as a novel, non-opioid option to treat moderate to severe acute pain.
Seminars
- Review recently published real-world and Phase IV evidence evaluating JOURNAVX use in clinical practice
- Examine emerging data on opioid-sparing outcomes and the evolving role of non-opioid therapies in acute pain management
- Explore prescribing patterns and treatment utilization trends from the growing body of post-launch evidence
- Discuss key considerations for advancing future pain therapies, including remaining challenges around efficacy, access, reimbursement, and demonstrating value beyond opioids
